REGENERON PHARMACEUTICALS, INC. Increase (Decrease) in Deferred Revenue
REGENERON PHARMACEUTICALS, INC. (REGN) reported Increase (Decrease) in Deferred Revenue of -$54.60 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-05-03
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$54.60M, a 540.29% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$53.98M.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$48.46M, a 122.40% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$23.05M.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2017 was -$113.10M, a 146.30% decline from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2016 was $244.27M, a 59.88% decline from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2015 was $608.89M.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2014 was -$8.40M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 3 month as first filed | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 6 month as first filed | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 9 month as first filed | Increase (Decrease) in Deferred Revenue 12 month | Increase (Decrease) in Deferred Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | -$54.60M 10-Q · filed 2018-05-03 | -$108.58M derived: sum of 2 quarters · filed 2018-05-03 | -$157.04M derived: sum of 3 quarters · filed 2018-05-03 | -$180.09M derived: sum of 4 quarters · filed 2018-05-03 | ||||
| 2017-12-31 | -$53.98M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | -$102.44M derived: sum of 2 quarters · filed 2018-02-08 | -$125.50M derived: sum of 3 quarters · filed 2018-02-08 | -$113.10M 10-K · filed 2018-02-08 | ||||
| 2017-09-30 | -$48.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$71.52M derived: sum of 2 quarters · filed 2017-11-08 | -$59.12M 10-Q · filed 2017-11-08 | -$97.02M derived: sum of 4 quarters · filed 2018-05-03 | ||||
| 2017-06-30 | -$23.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$10.65M 10-Q · filed 2017-08-03 | -$48.56M derived: sum of 3 quarters · filed 2018-05-03 | $167.76M derived: sum of 4 quarters · filed 2018-05-03 | ||||
| 2017-03-31 | $12.40M 10-Q · filed 2018-05-03 | -$25.51M derived: sum of 2 quarters · filed 2018-05-03 | $190.82M derived: sum of 3 quarters · filed 2018-05-03 | $165.47M derived: sum of 4 quarters · filed 2018-05-03 | ||||
| 2016-12-31 | -$37.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $178.42M derived: sum of 2 quarters · filed 2018-02-08 | $153.06M derived: sum of 3 quarters · filed 2018-02-08 | $244.27M 10-K · filed 2018-02-08 | ||||
| 2016-09-30 | $216.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $190.97M derived: sum of 2 quarters · filed 2017-11-08 | $282.18M 10-Q · filed 2017-11-08 | $267.00M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-06-30 | -$25.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $65.85M 10-Q · filed 2017-08-03 | $50.68M derived: sum of 3 quarters · filed 2018-02-08 | $691.43M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-03-31 | $91.20M 10-Q · filed 2017-05-04 | $76.03M derived: sum of 2 quarters · filed 2018-02-08 | $716.78M derived: sum of 3 quarters · filed 2018-02-08 | $707.55M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2015-12-31 | -$15.17M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $625.58M derived: sum of 2 quarters · filed 2018-02-08 | $616.35M derived: sum of 3 quarters · filed 2018-02-08 | $608.89M 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | $640.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $631.52M derived: sum of 2 quarters · filed 2016-11-04 | $624.06M 10-Q · filed 2016-11-04 | $612.19M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-06-30 | -$9.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$16.68M 10-Q · filed 2016-08-04 | -$28.55M derived: sum of 3 quarters · filed 2017-02-09 | -$41.19M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-03-31 | -$7.46M 10-Q · filed 2016-05-05 | -$16.14M 10-Q · filed 2015-05-07 | -$19.33M derived: sum of 2 quarters · filed 2017-02-09 | -$31.96M derived: sum of 3 quarters · filed 2017-02-09 | -$52.97M derived: sum of 4 quarters · filed 2017-02-09 | |||
| 2014-12-31 | -$11.87M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | -$24.51M derived: sum of 2 quarters · filed 2017-02-09 | -$45.51M derived: sum of 3 quarters · filed 2017-02-09 | -$8.40M 10-K · filed 2017-02-09 | $19.10M 10-K · filed 2015-02-12 | |||
| 2014-09-30 | -$12.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$33.64M derived: sum of 2 quarters · filed 2015-11-04 | $3.47M 10-Q · filed 2015-11-04 | $29.39M 10-Q · filed 2014-11-04 | -$17.21M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-06-30 | -$21.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $16.11M 10-Q · filed 2015-08-04 | $39.84M 10-Q · filed 2014-08-05 | -$4.58M derived: sum of 3 quarters · filed 2016-02-11 | -$13.81M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-03-31 | $37.11M 10-Q · filed 2015-05-07 | $16.43M derived: sum of 2 quarters · filed 2016-02-11 | $7.19M derived: sum of 3 quarters · filed 2016-02-11 | $2.08M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | -$20.68M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | -$29.92M derived: sum of 2 quarters · filed 2016-02-11 | -$35.03M derived: sum of 3 quarters · filed 2016-02-11 | -$41.50M 10-K · filed 2016-02-11 | -$27.97M 10-K · filed 2014-02-13 | |||
| 2013-09-30 | -$9.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | -$14.35M derived: sum of 2 quarters · filed 2014-11-04 | -$20.82M 10-Q · filed 2014-11-04 | -$33.29M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-06-30 | -$5.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | -$11.58M 10-Q · filed 2014-08-05 | -$24.05M derived: sum of 3 quarters · filed 2015-02-12 | -$34.99M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-03-31 | -$6.47M 10-Q · filed 2014-05-08 | -$18.94M derived: sum of 2 quarters · filed 2015-02-12 | -$29.88M derived: sum of 3 quarters · filed 2015-02-12 | -$38.42M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2012-12-31 | -$12.47M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | -$23.41M derived: sum of 2 quarters · filed 2015-02-12 | -$31.95M derived: sum of 3 quarters · filed 2015-02-12 | -$41.08M 10-K · filed 2015-02-12 | ||||
| 2012-09-30 | -$10.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | -$19.48M derived: sum of 2 quarters · filed 2013-11-05 | -$28.61M 10-Q · filed 2013-11-05 | -$36.44M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-06-30 | -$8.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$17.67M 10-Q · filed 2013-08-06 | -$25.50M derived: sum of 3 quarters · filed 2014-02-13 | -$37.44M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-03-31 | -$9.13M 10-Q · filed 2013-05-03 | -$16.96M derived: sum of 2 quarters · filed 2014-02-13 | -$28.90M derived: sum of 3 quarters · filed 2014-02-13 | -$39.15M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2011-12-31 | -$7.83M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | -$19.77M derived: sum of 2 quarters · filed 2014-02-13 | -$30.02M derived: sum of 3 quarters · filed 2014-02-13 | -$40.33M 10-K · filed 2014-02-13 | ||||
| 2011-09-30 | -$11.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | -$22.19M derived: sum of 2 quarters · filed 2012-10-24 | -$32.50M 10-Q · filed 2012-10-24 | -$47.01M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-06-30 | -$10.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | -$20.55M 10-Q · filed 2012-07-25 | -$35.06M derived: sum of 3 quarters · filed 2013-02-15 | $120.98M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-03-31 | -$10.31M 10-Q · filed 2012-04-26 | -$24.82M derived: sum of 2 quarters · filed 2013-02-15 | $131.22M derived: sum of 3 quarters · filed 2013-02-15 | $144.33M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2010-12-31 | -$14.51M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $141.53M derived: sum of 2 quarters · filed 2013-02-15 | $154.64M derived: sum of 3 quarters · filed 2013-02-15 | $158.15M 10-K · filed 2013-02-15 | ||||
| 2010-09-30 | $156.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $169.15M derived: sum of 2 quarters · filed 2011-10-27 | $172.66M 10-Q · filed 2011-10-27 | $156.54M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-06-30 | $13.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $16.62M 10-Q · filed 2011-07-28 | $498.00K derived: sum of 3 quarters · filed 2012-02-21 | -$16.75M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-03-31 | $3.51M 10-Q · filed 2011-05-03 | -$12.61M derived: sum of 2 quarters · filed 2012-02-21 | -$29.86M derived: sum of 3 quarters · filed 2012-02-21 | |||||
| 2009-12-31 | -$16.12M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | -$33.37M derived: sum of 2 quarters · filed 2012-02-21 | -$27.50M 10-K · filed 2012-02-21 | |||||
| 2009-09-30 | -$17.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | -$11.38M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | $5.87M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | -$26.83M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |